Background Anal cancer remains common among human immunodeficiency virus (HIV) patients. Chemoradiation has had mixed results. We evaluated outcome differences by HIV status. Methods We retrospectively analyzed 14 HIV+ and 72 HIV- anal cancer patients (2000 to 2013). Outcomes included chemoradiation tolerance, recurrence, and survival. Results HIV+ patients were more often male (100% vs 38%, P <.001) but diagnosed at similar stages (P =.49). They were less likely to receive traditional chemotherapy (36% vs 86%, P <.001). Recurrence (P =.55) and survival time (P =.48) were similar across groups. HIV+ patients had similar colostomy-free survival (P =.053). Receipt of 5-fluorouracil/mitomycin C (MMC) chemotherapy predicted recurrence-free and overall survival (Hazard ratios.278,.32). HIV status did not worsen recurrence (P =.71) or survival (P =.57). Conclusions HIV+ patients received more non-MMC-based chemoradiation but had equivalent colostomy-free, recurrence, and overall survival. Use of 5-fluorouracil/MMC chemotherapy increased after 2008.
|Original language||English (US)|
|Number of pages||8|
|Journal||American journal of surgery|
|State||Published - May 1 2016|
- Anal squamous cell carcinoma
ASJC Scopus subject areas